109P CTO1681 does not interfere with CAR T cell anti-tumor efficacy in vivo
Year: 2025
Type: article
Abstract: CD19-directed chimeric antigen receptor (CAR) T-cells have transformed outcomes for relapsed or refractory B-cell malignancies, achieving complete-response rates of 50–80%. Despite this transformative care, broader adoption and outpatient use of CAR T-cell treatments are constrained by the development of potentially life-threatening cytokine-release syndrome (CRS) and immune-cell associated neurotoxicity syndrome (ICANS) which require inpatient management. Current management of CRS/ICANS involves the use of tocilizumab or high-dose corticosteroids.
Source: Immuno-Oncology Technology
Authors: M. Howell, J. Craigo, M. Frigault, N. Todd, T. Whalen
Institutions: Massachusetts General Hospital, Mass General Brigham
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,340
OpenAlex ID: W7117304160
FWCI:
Cites:
Cited by:
Related to: